Press release
Myopia Pipeline 2024 | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics
Discover the latest drugs and treatment options in the Myopia Pipeline. Dive into DelveInsight's comprehensive report today! @ Myopia Pipeline Outlook [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Myopia Pipeline Report
* July 2024:- Hoffmann-La Roche - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).
* July 2024:- VIS Inc. - The goal of this clinical trial is to evaluate the safety and efficacy of using the VIS Opti-K System to enable monovision by providing temporary improvement in near vision through the treatment of the non-dominant eye of low myopic, emmetropic and low hyperopic presbyope subjects. The main questions it aims to answer are determining uncorrected near visual acuity at 40cm in the treated eye and subjective improvement as measured by the patient satisfaction questionnaire.
* DelveInsight's Myopia pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Myopia treatment.
* The leading Myopia Companies such as Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics , and others.
* Promising Myopia Therapies such as SYD-101 Dose 1, Alleance, NVK-002 Concentration 1, QLM3004 Concentration 1, Atropine Sulfate 01, and others.
Stay ahead with the most recent pipeline outlook for Myopia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Myopia Treatment Drugs [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Myopia Emerging Drugs Profile
* Atropine micro-formulation (MicroPine): Eyenovia
MicroPine is a proprietary microdose formulation of atropine used in our Optejet dispenser and product candidate for the prevention of progressive myopia (nearsightedness) in children. It is believed that Eyenovia's delivery technology is particularly well-suited for this application and patient population, potentially enabling children to easily self-administer atropine medication while minimizing dose-related side effects. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Myopia.
* SYD-101: Sydnexis
SYD-101 is an investigational low-dose atropine sulfate ophthalmic solution, 0.01% and 0.03%, designed to achieve efficacy, stability, and reduce discomfort for improved treatment continuity, according to studies on the treatment of childhood myopia. While published reports have shown low concentrations of compounded atropine to be effective, these solutions are limited by short shelf life and remain only stable if markedly acidified, which can also cause excessive burning and stinging in children, according to several studies on atropine for myopia. Currently, the drug is in phase III stage of its clinical trial for the treatment of Myopia.
Explore groundbreaking therapies and clinical trials in the Myopia Pipeline. Access DelveInsight's detailed report now! @ New Myopia Drugs [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Myopia Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Myopia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Myopia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Myopia Pipeline Report
* Coverage- Global
* Myopia Companies- Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics, and others.
* Myopia Therapies- SYD-101 Dose 1, Alleance, NVK-002 Concentration 1, QLM3004 Concentration 1, Atropine Sulfate 01, and others.
* Myopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Myopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Myopia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Myopia Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Myopia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Myopia - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Atropine micro-formulation (MicroPine): Eyenovia
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Myopia - Collaborations Assessment- Licensing / Partnering / Funding
* Myopia - Unmet Needs
* Myopia - Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myopia-pipeline-2024-sydnexis-sunhawk-vision-biotech-vyluma-eyenovia-cloudbreak-therapeutics-stuart-therapeutics]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myopia Pipeline 2024 | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics here
News-ID: 3611312 • Views: …
More Releases from ABNewswire
Daily Vibe Launches Comprehensive Fitness Products Store for Diverse Consumer Ma …
New fitness retailer Daily Vibe enters the market with targeted product selections designed to support active lifestyles across multiple demographics. The startup focuses on serving fitness enthusiasts, health-conscious consumers, and older adults seeking quality fitness products.
Founded by Ja'von L. Watson and Joyleena S. Watson, AGAIT International is a fast-growing Atlanta-based tech company dedicated to solving social and economic challenges through creative business and digital solutions. The company develops and manages…
Prolift Handling Brings Advanced pewag Lifting Technology to Ireland
Prolift Handling launches pewag levo Balancer and levo Compensator in Ireland - two advanced lifting solutions that improve safety and precision in heavy lifting operations through remote-controlled positioning and automatic load balancing.
Dublin, Ireland - Sep 30, 2025 - Prolift Handling, Ireland's exclusive pewag partner, today launched two advanced lifting solutions designed to tackle the industry's most challenging safety and precision requirements: the pewag levo Balancer and pewag levo Compensator.
The pewag…
A Gem of Joy ABA Breaks Barriers to Access with In-Home Therapy Services for Fam …
A Gem of Joy ABA offers in-home therapy services for Maryland families, breaking barriers to access and providing personalized support for children's development.
Maryland - A Gem of Joy ABA, a leading provider of autism therapy solutions, is making a transformative impact on families across Maryland by offering flexible and personalized in-home ABA Therapy. This innovative approach aims to break down barriers to care by delivering services directly to families' homes,…
Ontario Therapy Takes Action to Break Mental Health Stigma with DBT Therapy in B …
Ontario Therapy is expanding access to DBT therapy in Bradford, helping individuals overcome mental health challenges with effective, stigma-free support and coping strategies.
Bradford, ON - Ontario Therapy is taking significant steps to combat the stigma surrounding mental health by expanding access to Dialectical Behavior Therapy (DBT) in Bradford. With a mission to create more inclusive and supportive mental health care environments, Ontario Therapy is offering DBT therapy to help individuals…
More Releases for Myopia
Myopia Market Assessment & Forecast: Strategic Insights into Pediatric Myopia Ma …
Albany, United States - September 25, 2025 - DelveInsight, a leading provider of market intelligence and strategic consulting services in the healthcare sector, has released a comprehensive case study report on Myopia Market Assessment & Forecast, providing in-depth insights into the pediatric myopia landscape across Asia. This detailed study highlights prevalence trends, treatment paradigms, and market opportunities, equipping stakeholders with the actionable intelligence required to make informed decisions in the…
Myopia Control Lenses Market Forecast to Expand at 16.2% CAGR Amid Increasing Pe …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Myopia Control Lenses Market- (By Lens Type (Multifocal Lenses, Orthokeratology Lenses, Dual-Focus Lenses, Peripheral Defocus Lenses), By Age Group (Children, Adults), By Distribution Channel (Optometry Clinics, Optical Retail Stores, Online Retail)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Myopia Control Lenses Market is valued…
Latest Trends In Myopia Treatment Devices Market
A cutting-edge solution to the problem of myopia or nearsightedness is a wearable gadget for myopia control.
These tools, which frequently come in the shape of smart glasses or specialised contact lenses, make use of cutting-edge technology to control and slow the growth of myopia.
Wearable myopia control devices offer a proactive method of maintaining eye health by utilising features like changeable focus, customised vision correction, and real-time monitoring.
Request…
Myopia Control Devices Market - Seeing Beyond Blur: Revolutionary Myopia Devices …
Newark, New Castle, USA: The "Myopia Control Devices Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Myopia Control Devices Market: https://www.growthplusreports.com/report/myopia-control-devices-market/7989
This latest report researches the industry structure,…
Myopia Control Devices Market - Unlocking the Future of Clear Sight: Myopia Cont …
Newark, New Castle, USA - new report, titled Myopia Control Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Myopia Control Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Myopia Control Devices market. The report offers an overview of…
The Myopia Market is expected to be driven by the factors such as the rising cas …
The Myopia market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
The Myopia market report provides current treatment practices, emerging drugs, Myopia market share of the individual therapies, current and forecasted Myopia market Size from 2019 to…
